Patents Examined by Phyllis G. Spivack
  • Patent number: 8426453
    Abstract: Administration of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid is effective for treating a stomach or small intestine ulcer.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: April 23, 2013
    Assignee: Astellas Pharma Inc.
    Inventors: Masakatsu Kawakami, Yoshihiro Keto, Ken Ikeda, Mari Fukuda, Junji Sato
  • Patent number: 8399493
    Abstract: The present invention relates to methods for treating or controlling schizophrenia in a mammal using compounds having the Formula (I), wherein M1 and M2 are defined in the application.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: March 19, 2013
    Assignees: Janssen Pharmaceuticals, Inc., Addex Pharmaceuticals S.A.
    Inventors: Christelle Martine Bolea, Vanthea Nhem, Terry Patrick Finn, Emmanuel Christian Le Poul, Jean-Philippe Francois Christian Rocher, Robert Johannes Lutjens
  • Patent number: 8394785
    Abstract: The present invention relates to a method for the treatment and/or amelioration of urticaria, the method comprising the administration of a pharmaceutically active dose of a compound of formula I to a subject in need of such a treatment and/or amelioration.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: March 12, 2013
    Assignee: Jado Technologies GmbH
    Inventors: Tobias Braxmeier, Tim Friedrichson, Gary Jennings
  • Patent number: 8394833
    Abstract: The present invention relates to methods of treating emesis by administering to the subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: March 12, 2013
    Assignee: Helsinn Therapeutics (U.S.), Inc.
    Inventors: William R. Mann, William J. Polvino
  • Patent number: 8389556
    Abstract: The present invention relates to methods of using thiazolidinedione analogues of formula I: for treating Alzheimer's disease The terms R1, R2 and R3 are herein defined.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: March 5, 2013
    Assignee: Metabolic Soultions Development Company, LLC
    Inventors: Gerard R. Colca, Rolf F. Kletzien
  • Patent number: 8383680
    Abstract: A method is provided for the prevention and treatment of patients having impaired gastro-intestinal tract function. The method comprises the steps of administering to a patient requiring same free amino acids including about 9.0% to about 17.0% glutamic acid.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: February 26, 2013
    Assignee: Nestec S.A.
    Inventors: Constance Whippie, Olivier Ballevre, Julio Boza, Paul-Andre Finot
  • Patent number: 8372872
    Abstract: Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: February 12, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Lhanoo Gunawardhana, Himanshu Naik, Max Tsai
  • Patent number: 8362079
    Abstract: The invention relates to a method and composition for treatment of oxidative stress resulting from hemodialysis treatment in patients suffering from chronic kidney failure or End-Stage Renal Disease by administration of cystine, cysteine or mixtures thereof.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: January 29, 2013
    Assignee: Bio 3 Research S.R.L.
    Inventor: Francesco Santangelo
  • Patent number: 8361999
    Abstract: This invention discloses the use of compounds of the azetidinone family in treatment of cholesterol gallstone disease of the biliary tree in mammals. These drugs act by decreasing biliary cholesterol secretion, and at the same time increasing the biliary flow and the hepatic secretion of endogenous compounds (e.g. bile salts, phospholipids) into the bile, in turn, these endogenous compounds contribute to inhibiting precipitation and the formation of gallstones in the biliary tree.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: January 29, 2013
    Assignee: Pontificia Universidad Catolica de Chile
    Inventors: Juan Francisco Miquel Poblete, Flavio Nervi Oddone, Atillio Gianpietro Gigotti Rivera, Silvana Zanlungo Matsuhiro
  • Patent number: 8329756
    Abstract: The invention provides a method for treating or ameliorating colon cancer in a mammal comprising administering to the mammal a therapeutically effective amount of one or more compounds selected from the group consisting of compounds of Formula (1), (2), and a pharmaceutically acceptable salt or metabolite thereof.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: December 11, 2012
    Assignee: Oncophor, LLC
    Inventors: Gilles Klopman, Suman K. Chakravarti
  • Patent number: 8318811
    Abstract: A novel therapeutic and prophylactic agent for inflammatory bowel diseases and a method for treating inflammatory bowel diseases is provided. The agent comprises a 2-amino-1,3-propanediol derivative (e.g., 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol hydrochloride) represented by the chemical formula (1) or a pharmaceutically acceptable salt or hydrate thereof: The agent is useful in the treatment or prevention of Crohn's disease, Crohn's disease in large intestine, intestinal Behcet's disease, ulcerative colitis, bleeding rectal ulcer and pouchitis.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: November 27, 2012
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Ryotaro Kojima, Koichi Nakamaru, Tokutarou Yasue
  • Patent number: 8318708
    Abstract: This application relates to methods of treating and ameliorating fibrosis, such as fibrosis of the pancreas. In particular, the application relates to methods of using a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors) for the treatment of pancreatic fibrosis.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: November 27, 2012
    Assignees: Salk Institute for Biological Studies, University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Christopher Liddle, Nanthakumar Subramaniam, Caroline Flora Samer
  • Patent number: 8318792
    Abstract: A method for treating amyotrophic lateral sclerosis is disclosed wherein a compound having xanthine dehydrogenase inhibiting activity is administered.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: November 27, 2012
    Assignees: Nippon Medical School Foundation, National University Corporation Tottori University
    Inventors: Takeshi Nishino, Yasuko Abe, Shinsuke Kato
  • Patent number: 8314077
    Abstract: The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: November 20, 2012
    Assignee: Luitpold Pharmaceuticals, Inc.
    Inventors: Nigel L. Webb, Matthews O. Bradley, Charles S. Swindell, Victor E. Shashoua
  • Patent number: 8314149
    Abstract: A method is disclosed wherein semapimod, and/or the mesylate salt thereof, is administered for the treatment of necrotizing enterocolitis.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: November 20, 2012
    Assignees: Feering B.V., University of Pittsburgh—Of The Commonwealth System Of Higher Education
    Inventors: Ruben Zamora, Henri R. Ford, Thais Sielecki-Dzurdz, Vidal F. De La Cruz
  • Patent number: 8309569
    Abstract: The present invention provides methods of treating diarrhea-associated irritable bowel syndrome (IBS-D) following rifaximin administration.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: November 13, 2012
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: William Forbes, Lorin Johnson
  • Patent number: 8288391
    Abstract: The present invention relates to blocking salt taste using compounds of Formula I as defined herein.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: October 16, 2012
    Assignee: Parion Sciences, Inc.
    Inventors: Michael R. Johnson, Richard C. Boucher, Andrew J. Hirsh
  • Patent number: 8288427
    Abstract: A method of treating emesis with growth hormone secretagogues, particularly ipamorelin.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: October 16, 2012
    Assignee: Helsinn Therapeutics (U.S.), Inc.
    Inventors: William R. Mann, William J. Polvino
  • Patent number: RE43916
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: January 8, 2013
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke
  • Patent number: RE44159
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: April 16, 2013
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke